Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase I-II Clinical Trial

NCT02735928 is registered in ClinicalTrials.gov with Catholic University of the Sacred Heart as lead sponsor.

NCT NCT02735928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02735928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase I-II Clinical Trial
Lead sponsor
Catholic University of the Sacred Heart
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2016
Completion date
June 16, 2022
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian epithelial cancer recurrent, platinum-resistant